Articles
Page 15 of 20
-
Citation: BMC Pharmacology 2007 7(Suppl 1):P69
-
Exercise training effects on vascular reactivity and metabolic parameters of high caloric-fed Wistar rats
Citation: BMC Pharmacology 2007 7(Suppl 1):P67 -
Hyper-contractility and impaired cGMP signaling in the BKCa channel deletion model of erectile dysfunction
Citation: BMC Pharmacology 2007 7(Suppl 1):P65 -
Effects of BAY 41–2272 on smooth muscle tone, soluble guanylyl cyclase activity and NADPH oxidase activity/expression in corpus cavernosum from wild-type, neuronal and endothelial NOS null mice
Citation: BMC Pharmacology 2007 7(Suppl 1):P58 -
ANP changes microvascular endothelial barrier function in vivo
Citation: BMC Pharmacology 2007 7(Suppl 1):P53 -
Increased ventilatory lung stretch alters the effect of soluble guanylyl cyclase-derived cGMP on endothelial barrier function in isolated mouse lungs
Citation: BMC Pharmacology 2007 7(Suppl 1):P51 -
Desensitization of soluble guanylyl cyclase, the NO-receptor, by S-nitrosylation
Citation: BMC Pharmacology 2007 7(Suppl 1):P50 -
Regulation of cGMP by phosphodiesterases (PDEs) in the central nervous system
Citation: BMC Pharmacology 2007 7(Suppl 1):S48 -
cGMP signaling and bifurcation of sensory axons at the dorsal root entry zone of the spinal cord
Citation: BMC Pharmacology 2007 7(Suppl 1):S47 -
cGMP-dependent kinase I supports formation of associative fear memory and long-term potentiation in the lateral amygdala
Citation: BMC Pharmacology 2007 7(Suppl 1):P46 -
NPR-A gene deletion reverses vascular dysfunction associated with sepsis
Citation: BMC Pharmacology 2007 7(Suppl 1):P44 -
The formation of a Ca2+-dependent complex of C-reactive protein and very low density lipoprotein causes the biphasic transmittance waveform
Citation: BMC Pharmacology 2007 7(Suppl 1):P42 -
Supersensitivity of muscarinic receptors in rat isolated detrusor smooth muscle (DSM) after chronic nitric oxide inhibition
Citation: BMC Pharmacology 2007 7(Suppl 1):P41 -
Fresh look on old substances – new class of NO-independent regulators of soluble guanylyl cyclase activity and function
Citation: BMC Pharmacology 2007 7(Suppl 1):P40 -
Pharmacokinetic and pharmacodynamic study of a novel chimeric natriuretic peptide, CD-NP, in the normal dog
Citation: BMC Pharmacology 2007 7(Suppl 1):P38 -
PDE9A, PDE10A, and PDE11A expression in rat trigeminovascular pain signalling system: role in pathogenesis of migraine?
Citation: BMC Pharmacology 2007 7(Suppl 1):P36 -
Hsp90 and sGC-mediated vasorelaxation
Citation: BMC Pharmacology 2007 7(Suppl 1):S35 -
cGMP-Protein kinase G signaling pathway is involved in stimulation of Leydig cell steroidogenesis
Citation: BMC Pharmacology 2007 7(Suppl 1):P34 -
Influence of heme metabolism and redox regulation of sGC in the control of vascular function
Citation: BMC Pharmacology 2007 7(Suppl 1):S33 -
Vascular smooth muscle PDE5 is much more sensitive to N-alkylated zaprinast than platelet PDE5
Citation: BMC Pharmacology 2007 7(Suppl 1):P32 -
Melanocytes: interface of cell biology and pathobiology with a focus on nitric oxide and cGMP signaling
Citation: BMC Pharmacology 2007 7(Suppl 1):S31 -
Integrin receptor subtype antagonism augments BNP-mediated cGMP generation in cultured human cardiac fibroblasts: evidence for particulate guanylate cyclase receptor and integrin receptor cross-talk
Citation: BMC Pharmacology 2007 7(Suppl 1):P30 -
Phosphorylation of cAMP hydrolyzing PDE (PDE3A) by cGMP-dependent protein kinase (PKG) in human platelets
Citation: BMC Pharmacology 2007 7(Suppl 1):S29 -
Cardiovascular effects of the soluble guanylyl cyclase activator BAY 58–2667 in anesthetized dogs
Citation: BMC Pharmacology 2007 7(Suppl 1):P28 -
Molecular steps in sGC activation
Citation: BMC Pharmacology 2007 7(Suppl 1):S27 -
Characterization of an epitope-tagged guanylyl cyclase-A receptor
Citation: BMC Pharmacology 2007 7(Suppl 1):P26 -
Specificity of commonly used cyclic nucleotides with PKA, PKG and Epac-implementing microcalorimetry to determine PDE activities
Citation: BMC Pharmacology 2007 7(Suppl 1):S25 -
cGMP compartments in cardiac myocytes
Citation: BMC Pharmacology 2007 7(Suppl 1):S23 -
Rapid monitoring of intracellular cGMP
Citation: BMC Pharmacology 2007 7(Suppl 1):S21 -
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile and decreases peripheral vascular resistance in healthy male volunteers
Citation: BMC Pharmacology 2007 7(Suppl 1):P20 -
Effect of new sildenafil analogues in the rabbit isolated aorta
Citation: BMC Pharmacology 2007 7(Suppl 1):P19 -
New mouse models for the analysis of cGMP signalling
Citation: BMC Pharmacology 2007 7(Suppl 1):S19 -
Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients
Citation: BMC Pharmacology 2007 7(Suppl 1):P18 -
Guanylyl cyclase-A mediated endothelial actions of natriuretic peptides are critically involved in postischemic reperfusion
Citation: BMC Pharmacology 2007 7(Suppl 1):S17 -
Chronic inhibition of cyclic GMP phosphodiesterase 5A may promote pressure overload-induced chamber dilatation in mice
Citation: BMC Pharmacology 2007 7(Suppl 1):P17 -
Analysis of mice with genetic modifications of PKG I
Citation: BMC Pharmacology 2007 7(Suppl 1):S15 -
Pharmacological characterization of the novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum
Citation: BMC Pharmacology 2007 7(Suppl 1):P13 -
Run training ameliorates the established erectile dysfunction in rats under long-term nitric oxide (NO) blockade
Citation: BMC Pharmacology 2007 7(Suppl 1):P11 -
The emerging role of PDE5 inhibition in heart failure
Citation: BMC Pharmacology 2007 7(Suppl 1):S10 -
BAY 58–2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile
Citation: BMC Pharmacology 2007 7(Suppl 1):S9 -
Targeting heme-oxidized soluble guanylate cyclase with BAY 58-2667 in experimental heart failure
Citation: BMC Pharmacology 2007 7(Suppl 1):P9 -
BAY 63–2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile, improves cardiopulmonary haemodynamics and has therapeutic potential in pulmonary hypertension
Citation: BMC Pharmacology 2007 7(Suppl 1):S8 -
Relaxation of vascular smooth muscle by the cGMP-kinase substrate IRAG
Citation: BMC Pharmacology 2007 7(Suppl 1):P8 -
Exploiting the natriuretic peptide system for the treatment of pulmonary hypertension
Citation: BMC Pharmacology 2007 7(Suppl 1):S7 -
Selective activation of hippocampal guanylyl cyclase by a novel NO mimetic nitrate ester
Citation: BMC Pharmacology 2007 7(Suppl 1):P6 -
Relaxant effect of BAY 41–2272 in the rabbit isolated detrusor smooth muscle (DSM): involvement of cGMP-independent mechanisms
Citation: BMC Pharmacology 2007 7(Suppl 1):P4 -
Role of the sGC activator ataciguat sodium (HMR1766) in cardiovascular disease
Citation: BMC Pharmacology 2007 7(Suppl 1):S4 -
Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO
The rational design of peptide-based specific inhibitors of the caspase family members using their X-ray crystallographies is an important strategy for chemical knockdown to define the critical role of each en...
Citation: BMC Pharmacology 2007 7:8 -
Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa
The nasal tissue uptake and metabolism of ciclesonide, a new-generation corticosteroid under investigation for treatment of allergic rhinitis, to its active metabolite, desisobutyryl-ciclesonide (des-CIC), was...
Citation: BMC Pharmacology 2007 7:7 -
Clofibrate treatment in pigs: Effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents
In rodents treatment with fibrates causes hepatocarcinogenesis, probably as a result of oxidative stress and an impaired balance between apoptosis and cell proliferation in the liver. There is some debate whet...
Citation: BMC Pharmacology 2007 7:6